How India Exports Acetaminophen to the World

In the United States, acetaminophen is regulated by the Food and Drug Administration (FDA). The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for acetaminophen, indicating a competitive market with multiple generic manufacturers. Notably, CorePharma LLC received approval for acetaminophen extended-release tablets (NDA #076200) on August 11, 2004.

The FDA has implemented specific regulatory measures to ensure the safety of acetaminophen products. In January 2011, the agency announced steps to reduce the maximum dosage unit strength of acetaminophen in prescription drug products to prevent liver damage due to overdosing. Additionally, in 2024, the FDA proposed an administrative order to amend the Over-the-Counter Monograph M013, requiring the addition of a warning about severe skin reactions associated with acetaminophen use.

Given that 73.2% of India's acetaminophen exports are destined for the U.S., Indian manufacturers must adhere to these stringent FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), acetaminophen (paracetamol) is subject to comprehensive regulatory oversight. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require marketing authorization for all medicinal products. The Human Medicines Regulations 2012, effective from August 14, 2012, consolidate UK laws concerning medicinal products, including manufacturing, distribution, and pharmacovigilance. (health-ni.gov.uk)

Compliance with Good Manufacturing Practice (GMP) standards is mandatory in both jurisdictions. These standards ensure product quality and safety, necessitating that Indian exporters meet EU and UK GMP requirements to access these markets.

Acetaminophen is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is crucial for Indian manufacturers to ensure product quality and facilitate international trade.

In India, acetaminophen is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). Manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for export purposes, ensuring compliance with national regulations.

Acetaminophen is a well-established generic drug with no active patents or exclusivity rights, allowing for widespread generic competition. This competitive landscape is reflected in India's export market, with 266 active exporters supplying acetaminophen to 104 countries.

In January 2024, the FDA proposed an administrative order to amend the Over-the-Counter Monograph M013, requiring the addition of a warning about severe skin reactions associated with acetaminophen use.

In February 2024, the EMA published a study titled "Safety Profile of Extended Release (650 mg) Acetaminophen Products in the United States," analyzing data from the National Poison Data System and FDA Adverse Event Reporting System. (catalogues.ema.europa.eu)

In March 2024, the UK's Department of Health emphasized the importance of compliance with the Human Medicines Regulations 2012, which govern the manufacture, importation, and distribution of medicinal products, including acetaminophen. (health-ni.gov.uk)

These developments highlight the dynamic regulatory environment surrounding acetaminophen, necessitating continuous monitoring by Indian exporters to ensure compliance and maintain market access.

India is a leading producer of acetaminophen (paracetamol) APIs, yet it heavily depends on China for key starting materials (KSMs) such as para-aminophenol (PAP). This reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, environmental regulations, and logistical disruptions in China. For instance, in 2020, China's stringent environmental policies led to the shutdown of several chemical plants, causing significant supply disruptions and price escalations for Indian pharmaceutical manufacturers.

The COVID-19 pandemic further highlighted these dependencies. In early 2020, Chinese API manufacturers resumed production after initial lockdowns, but logistical challenges persisted, hindering timely shipments to India and other countries. (globaltimes.cn) Such events underscore the critical need for India to develop domestic capabilities in producing essential KSMs to mitigate risks associated with external supply chain disruptions.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in India's acetaminophen exports. The top five exporters account for 79.6% of the total export value, with Granules India Limited alone contributing 56.1% ($130.1 million). This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could disrupt the global supply chain.

To address such vulnerabilities, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of critical APIs and KSMs. While the scheme has incentivized investment in API production, its impact on reducing supplier concentration in the acetaminophen market remains to be fully realized.

Recent geopolitical events have further strained the acetaminophen supply chain. In February 2026, the closure of the Strait of Hormuz following military conflicts disrupted the supply of raw materials and increased shipping costs. This chokepoint is vital for global oil and chemical shipments, and its disruption has had cascading effects on industries reliant on these inputs.

Additionally, tensions in the Red Sea and the Strait of Hormuz have led to rerouting of shipping lanes, adding approximately 10 to 14 days to transit times. Such delays have impacted the timely delivery of pharmaceutical products, including acetaminophen, leading to potential shortages and increased costs.

• Diversify Raw Material Sources: Invest in domestic production of critical KSMs like PAP to reduce dependency on Chinese imports.

• Expand Supplier Base: Encourage the growth of small and medium-sized API manufacturers to decrease supplier concentration and mitigate single-source risks.

• Enhance Supply Chain Resilience: Develop strategic reserves of essential raw materials and APIs to buffer against geopolitical and logistical disruptions.

• Strengthen Regulatory Compliance: Ensure that domestic manufacturers adhere to international quality standards to maintain a competitive edge in the global market.

• Monitor Geopolitical Developments: Establish a dedicated task force to assess and respond to international events that may impact the pharmaceutical supply chain.

RISK_LEVEL: HIGH